Impact of atypical presenting symptoms on door-to-balloon time and mortality outcomes in ST-segment elevation
Jeng-Fu Huang1, Shi-Quan Zhang1, Yu-Ting Hsiao1
1Department of Emergency Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, No. 539, Zhongxiao Road, East District, Chiayi City, 600, Taiwan.
Background:
The impact of atypical symptom presentation in ST-segment elevation myocardial infarction (STEMI) on treatment timeliness and long-term outcomes remains insufficiently characterized. This study aimed to examine the association between symptom presentation and delays in door-to-balloon (DTB) time components and short- and long-term mortality, and to identify triage characteristics independently associated with atypical STEMI presentation.
Methods:
We conducted a retrospective cohort study of STEMI patients undergoing primary percutaneous coronary intervention at a tertiary hospital in Taiwan between 2013 and 2022. Symptom presentation was classified as typical or atypical based on emergency department triage records. Primary outcomes included delays in DTB components and all-cause mortality at 30 days, 1 year, and 3 years. The secondary outcome was identification of triage characteristics associated with atypical presentation. Multivariable Cox and logistic regression models were used.
Results:
Of 807 patients, 13.5% presented with atypical symptoms. Atypical presentation was independently associated with higher 30-day (aHR: 2.20, 95% CI: 1.15-4.21), 1-year (aHR: 1.91, 95% CI: 1.09-3.37), and 3-year (aHR: 1.73, 95% CI: 1.04-2.87) mortality. It was also linked to delays in door-to-ECG (aOR: 11.52, 95% CI: 6.04-22.06), activation-to-Cath lab-arrival (aOR: 1.71, 95% CI: 1.04-2.80), and Cath lab-arrival-to-balloon time (aOR: 1.95, 95% CI: 1.24-3.06). Older age, female sex, diabetes, cerebrovascular disease, tachycardia, and hypotension were independently associated with atypical presentation.
Conclusions:
Atypical STEMI presentation is associated with treatment delays and increased short- and long-term mortality. Early identification of high-risk patients may improve timely care and clinical outcomes.
Clinical Trial Number:
Not applicable.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome IV: Interprofessional Care
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Mitral Stenosis II: Clinical features and Diagnostic Tests
